Navigation Links
Lombardi Cancer Center's Toretsky awarded prestigious Burroughs Wellcome Fund Award
Date:3/7/2008

ity Medical Center, led by Milton Brown, Ph.D, is uniquely positioned at the interface of chemistry and medicine to facilitate the translation of basic science towards new medical therapies.

"It's a privilege to work with Milt and a team of chemists and biologists to address a specific cancer problem," said Toretsky. "This kind of interaction is required to truly impact the progress of translational research and drug discovery. Ewing's sarcoma is rare, but our work has the potential to improve treatment not only for patients with this disease but for others who have cancers with similar molecular characteristics."

His sentiments were echoed by Louis M. Weiner, MD, director of the Lombardi Comprehensive Cancer Center, who noted, "The collaboration between Jeff Toretsky and Milt Brown exemplifies the Lombardi's commitment to creating multi-investigator collaborations that focus on translational research. Their work will directly lead to the improved understanding and treatment of Ewing's sarcoma. Support from the Burroughs Wellcome Fund will provide critical resources to enable this important work."

Toretsky divides his time between clinical practice as a pediatric hematologist/oncologist and his research laboratory. In addition to Ewing's sarcoma, his clinical interests include rare pediatric hematology diseases and childhood cancers, in particular osteosarcoma (bone cancer) and synovial sarcoma.

Toretsky received his BS from the University of Wisconsin, Madison in 1984 and his MD in 1988 from the University of Minnesota. He completed his pediatric residency at the Medical College of Virginia in 1991, and his pediatric oncology fellowship at the National Cancer Institute Pediatric Branch in 1994. He came to Lombardi in 2002 from the Departments of Pediatrics and Biochemistry and Molecular Biology at the University of Maryland.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 2Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 3Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 4Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 5Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 6Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 7Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 8Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer 9